Figure 1: Venn diagram showing distribution of prescribing by brand loyalty

- 7.0% of rheums prescribe Xeljanz but not Olumiant
- 16.2% of rheums prescribe Xeljanz
- 12.1% of rheums prescribe Olumiant but not Xeljanz
- 64.7% of Non JAK Prescribers

Source: Ipsos Healthcare RA Therapy Monitor
n= 431 rheumatologists (accumulated waves)